Cilian erhält BMBF-Förderung für Enzymersatz-Therapie mit Ciliaten-Lipase Die Cilian AG erhält im Rahmen des Fördermoduls KMU-innovativ Finanzmittel zur Entwicklung einer neuen Therapie für exokrine Pankreasunterfunktion

Transmissions between mammals demonstrate the serious dangerousness that mutations of avian influenza viruses might lead to an epidemic or pandemic for humans Public debate, press

Press release: Bird flu threat calls for new vaccine technology The current avian influenza outbreak among mammals in Spain shows the potential of the influenza

Cilian´s CIBEX expression platform to be presented on CPhI International 2022 Cilian’s unique and novel CIBEX expression platform for biopharmaceuticals will be displayed on a

Video: In vivo efficacy of the recombinant influenza vaccine candidate CiFlu derived from the CIBEX system On September 3, 2022 Cilian presented at the 8th

City council and Technologieförderung Münster visiting Cilian AG Members of Münster’s city council that at the same time serve on the Supervisory Board of its

Defeating the Corona Virus (2019-Cov) in less than Six Months Münster, January 30, 2020. Since the outbreak of a new Corona virus late 2019 at

Frontiers in Immunology, an international, peer-reviewed journal publishes article of an influenza vaccine produced in ciliates Münster, Germany, 9 December 2019, Cilian AG, a biopharmaceutical

Cilian publishes article in mAbs. “Leading journal presents a proof of principle study for Cilian’s expression technology CIPEXSystem to produce monoclonal antibody candidates. Münster, Germany,

Cilian publishes articles in the European Journal of Gastroenterology & Hepatology. “Leading journal presents in vitro studies for endogenous Ciliate lipases as therapeutic candidates for